SOURCE-BASED EDITORIAL GUIDE · SPECIALIST REVIEW PENDING

What the evidence says

Cellular senescence is one of the mechanisms discussed in the hallmarks of aging framework. Senolytic research asks whether selectively targeting senescent cells can improve specific outcomes.

A 2019 open-label pilot studied dasatinib plus quercetin in people with idiopathic pulmonary fibrosis. Its small, disease-specific design cannot establish general anti-aging efficacy.

THE TAKEAWAY

Pilot studies generate questions for controlled research.

Where the evidence stops

This is not evidence to self-administer senolytics or to recommend supplements as senolytic treatment.

Read the original sources

Source pages checked on 23 October 2026. This is not the publication date of each study. Original sources may be in English.

Justice et al. · EBioMedicine, 2019pubmed.ncbi.nlm.nih.gov · Sources checked: 2026-10-23López-Otín et al. · Cell, 2023pubmed.ncbi.nlm.nih.gov · Sources checked: 2026-10-23

Questions worth taking further

  • Was the outcome measured in humans, animals or cells?
  • Does the study population match the people in the claim?
  • What benefits, harms and uncertainties remain unmeasured?